Search
Menu
Home
HTB
2025
January
January 2025
Contents
Editorial
Looking back through 2024 and forward to 2025…
i-Base appeal: Q&A services and the website in 2025
Special reports
Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection
ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir
Antiretrovirals
EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old
Transient impact of lenacapavir against MDR HIV-2 without other active ART
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
Treatment access
US issues temporary waiver to re-enable PEPFAR
IAS statement: PEPFAR freeze threatens millions of lives
Trump bans travel for US government scientists, presentations restricted, language bans, documents disappearing
Pregnancy
BHIVA pregnancy guidelines online for comment: deadline 25 January
mpox
Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1
Tecovirimat news continues: Japan approval includes mpox indication
HTB RSS
Early access
Vaccination effectively limits mpox progression: lower efficacy in people living with HIV
27 May 2025
US update guidelines for statin use in people living with HIV
26 May 2025
HIV activists in the US call for action and Zachie Achmet brings South African perspective
26 May 2025
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
All early access reports
Current issues
May 2025
April 2025
March 2025
Back issues
Special report
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate